Maria Cherska: The Future of Familial Hypercholesterolemia Care
Maria Cherska, The head of cardiology department at The State Institution «V.P. Komisarenko Institute of Endocrinology and Metabolism», shared a post on LinkedIn about a recent article by Mohamad Warda et al., published in Lipids in Health and Disease։
”Familial Hypercholesterolemia (FH): Rethinking Detection and Long-Term Management – Insights from EAS 2025
Familial hypercholesterolemia remains substantially underdiagnosed worldwide, despite being a major driver of premature atherosclerotic cardiovascular disease. The gap between guideline recommendations and real-world implementation is still significant.
In this expert interview from EAS 2025, Prof. Gerald Watts discusses the evolving clinical strategy for FH management — from early identification and cascade screening to long-term LDL-C control and residual risk reduction.
Key clinical takeaways:
- Systematic early detection is critical
- Cascade screening should be integrated into routine practice
- Aggressive and sustained LDL-C lowering is essential
- Residual cardiovascular risk persists even after LDL-C reduction
FH is not a rare condition – it is a common, lifelong, high-risk state that requires proactive and structured management.
For cardiologists, lipidologists, endocrinologists, internists, and preventive cardiology specialists focused on high-risk patient care and long-term ASCVD prevention.
How do you currently implement cascade screening and long-term LDL-C control in FH patients?”
Title: Lipid rafts: novel therapeutic targets for metabolic, neurodegenerative, oncological, and cardiovascular diseases
Authors: Mohamad Warda, Samet Tekin, Mahmoud Gamal, Nagwa Khafaga, Fikret Çelebi, Giovanni Tarantino
Stay updated on all scientific advances with Hemostasis Today.
-
Jun 25, 2026, 15:56Wolfgang Miesbach: Building the Future of Gene Therapy – From Centre Readiness to Long-Term Patient Care
-
Jun 25, 2026, 15:46Amber Yates: Making a Meaningful Difference for People Living with Sickle Cell Disease
-
Jun 25, 2026, 15:43Nancy Cavey: Navigating Disability Benefits for Patients with Immune Thrombocytopenia
-
Jun 25, 2026, 15:28Damon Race: Pursuing Long-Term Expression in Hemophilia A Gene Therapy
-
Jun 25, 2026, 15:23Jonas Kingo: ISTH 2026 in Paris Brings the Global Hemostasis Community Together
-
Jun 25, 2026, 15:21Balancing Therapeutic Progress and Emergency Preparedness in Hemophilia – CRH French Reference Center for Hemophilia Lyon
-
Jun 25, 2026, 15:06Ifeanyichukwu Ifechidere: What If One of the Biggest Myth Fact About APS is Hidden in its Name?
-
Jun 25, 2026, 15:05Gopal Patidar: Advancing Haemovigilance and Global Collaboration at ISBT 2026
-
Jun 25, 2026, 14:52Violeta Jardin: Measuring Antifibrinolytic Effect to Improve Tranexamic Acid Safety